12
|
Development of an in vitro assay to assess bispecific T cell engager using T cells from CD3e humanized mice
|
|
237
|
In vitro potency assays for immune checkpoint blockade using human primary cells, murine HuGEMM™ immune cells, and patient-derived tumor organoids
|
|
245
|
Human TLR8 knock-in mice potentiate immunotherapy responses of MC38 syngeneic tumors
|
|
527
|
Tumor organoid and immune cell co-culture system potentiates immuno-oncology drug development
|
|
647
|
Evaluation of efficacy and toxicity of CD137 immunotherapy with urelumab-mIgG1 chimeric antibody in CD137 HuGEMM
|
|
677
|
Evaluation of anti-PD-1 efficacy in germ-free and antibiotic-treated SPF mice bearing MC38 tumors
|
|
738
|
Establishment and application of a series of genetically engineered mouse derived breast cancer homograft models
|
|
